4074-51-5

Usage

Uses

Used in Pharmaceutical Industry:
1-(4-Isopropoxyphenyl)ethanone is used as a synthetic intermediate for the preparation of p-substituted acetophenone compounds, which are essential in the development of pharmaceuticals with diverse therapeutic applications, including the treatment of various diseases and disorders.
Used in Chemical Synthesis:
1-(4-Isopropoxyphenyl)ethanone serves as a key building block in the synthesis of a wide range of organic compounds, such as dyes, pigments, and other specialty chemicals. Its unique structure allows for further functionalization and modification, making it a valuable component in the development of new materials and products.
Used in Research and Development:
Due to its structural characteristics, 1-(4-isopropoxyphenyl)ethanone is also utilized in research and development for the exploration of new chemical reactions, mechanisms, and the synthesis of novel compounds with potential applications in various fields, such as materials science, pharmaceuticals, and agrochemicals.

InChI:InChI=1/C11H14O2/c1-8(2)13-11-6-4-10(5-7-11)9(3)12/h4-8H,1-3H3

Upstream product

• 2741-16-4 isopropoxybenzene 
• 108-24-7 acetic anhydride 
• 88-69-7 2-(1-methylethyl)phenol 
• 75-36-5 acetyl chloride 
• 75-15-0 carbon disulfide 
• 7446-70-0 aluminium trichloride 
• 403-42-9 1-(4-fluorophenyl)ethanone 
• 67-63-0 isopropyl alcohol 
• 99-90-1 para-bromoacetophenone 
• 99-91-2 para-chloroacetophenone 
• 99-93-4 4-Hydroxyacetophenone 
• 75-30-9 2-iodo-propane 
• 108-95-2 phenol 
• 82255-58-1 5-Acetyl-2,2-dimethyl-1,3-benzoxathiole 

Downstream Products

• 63957-31-3 1-(4-isopropoxy-phenyl)-3-piperidino-propan-1-one; hydrochloride 
• 858834-55-6 1-(4-isopropoxy-phenyl)-3-phenyl-propane-1,3-dione 
• 78382-08-8 C₁₂H₁₈N₄OS 
• 1194065-41-2 5-(1-(4-isopropoxyphenyl)ethylidene)-2,2-dimethyl-1,3-dioxane-4,6-dione 
• 55784-02-6 4-[(4-isopropoxy-phenyl)-thioacetyl]-morpholine 
• 1243257-43-3 C₁₅H₂₃NO₃ 
• 1243257-34-2 2-[2-(4-isopropoxyphenylmorpholino-4-yl)ethyl 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-acetate] hydrochloride 
• 1431475-32-9 (E)-N-(1-(4-isopropoxyphenyl)ethylidene)aniline 
• 99259-75-3 C₁₈H₁₈O₂ 
• 3654-50-0 3-(3-hydroxyphenyl)-1-(4-hydroxyphenyl)-2-propen-1-one 

Relevant academic research and scientific papers

NEGATIVE ALLOSTERIC MODULATION OF GLUN3-CONTAINING N-METHYL-D-ASPARTATE RECEPTORS

Disclosed are negative allosteric modulators of GluN3-containing NMDA receptors. In general, these compounds are highly selective for GluN3 (such as GluN3A and/or GluN3B) over GluN1 and/or GluN2. They can function as non-competitive antagonists with activity that is independent of membrane potential, glycine concentration, and extracellular pH. Also disclosed are pharmaceutical formulations of the negative allosteric modulators. These compounds can be used to enhance synaptic function and/or treating a neurological condition or disorder. Exemplary neurological conditions or disorders include, but are not limited to, major mental disorders, conditions that involve basal ganglia or altered dopamine, substance abuse/addiction or predisposition to substance abuse/addiction, pain disorders, developmental delay or situations with impaired learning, memory, and/or cognition, acute neuronal or glial injuries, and circuit disorders.

Solar-driven tandem photoredox nickel-catalysed cross-coupling using modified carbon nitride

Nickel-catalysed aryl amination and etherification are driven with sunlight using a surface-modified carbon nitride to extend the absorption of the photocatalyst into a wide range of the visible region. In contrast to traditional homogeneous photochemical methodologies, the lower cost and higher recyclability of the metal-free photocatalyst, along with the use of readily available sunlight, provides an efficient and sustainable approach to promote nickel-catalysed cross-couplings. This journal is

Rationally Designed Polypharmacology: α-Helix Mimetics as Dual Inhibitors of the Oncoproteins Mcl-1 and HDM2

Protein–protein interactions (PPIs), many of which are dominated by α-helical recognition domains, play key roles in many essential cellular processes, and the dysregulation of these interactions can cause detrimental effects. For instance, aberrant PPIs involving the Bcl-2 protein family can lead to several diseases including cancer, neurodegenerative diseases, and diabetes. Interactions between Bcl-2 pro-life proteins, such as Mcl-1, and pro-death proteins, such as Bim, regulate the intrinsic pathway of apoptosis. p53, a tumor-suppressor protein, also has a pivotal role in apoptosis and is negatively regulated by its E3 ubiquitin ligase HDM2. Both Mcl-1 and HDM2 are upregulated in numerous cancers, and, interestingly, there is crosstalk between both protein pathways. Recently, synergy has been observed between Mcl-1 and HDM2 inhibitors. Towards the development of new anticancer drugs, we herein describe a polypharmacology approach for the dual inhibition of Mcl-1 and HDM2 by employing three densely functionalized isoxazoles, pyrazoles, and thiazoles as mimetics of key α-helical domains of their partner proteins.

Identification of new aryl hydrocarbon receptor (AhR) antagonists using a zebrafish model

A new series of 1,3-diketone, heterocyclic and α,β-unsaturated derivatives were synthesized and evaluated for their AhR antagonist activity using zebrafish and mammalian cells. Compounds 1b, 2c, 3b and 5b showed significant AhR antagonist activity in a transgenic zebrafish model. Among them, compound 3b, and 5b were found to have excellent AhR antagonist activity with IC50 of 3.36 nM and 8.3 nM in a luciferase reporter gene assay. In stem cell proliferation assay, compound 5b elicited marked HSC expansion.

Chalcone derivatives enhance ATP-binding cassette transporters A1 in human THP-1 macrophages

Atherosclerosis is a process of imbalanced lipid metabolism in the vascular walls. The underlying pathology mainly involves the deposition of oxidized lipids in the endothelium and the accumulation of cholesterol in macrophages. Macrophages export excessive cholesterol (cholesterol efflux) through ATP-binding cassette transporter A1 (ABCA1) to counter the progression of atherosclerosis. We synthesized novel chalcone derivatives and assessed their effects and the underlying mechanisms on ABCA1 expression in macrophages. Human THP-1 macrophages were treated with synthetic chalcone derivatives for 24 h. In Western blot and flow cytometry analyses, a chalcone derivative, (E)-1-(3,4-diisopropoxyphenyl)-3-(4-isopropoxy-3-methoxyphenyl)prop- 2-en-1-one (1m), was observed to significantly enhance ABCA1 protein expression in THP-1 cells (10 μM, 24 h). Levels of mRNA of ABCA1 and liver X receptor alpha (LXRα) were quantified using a real-time quantitative polymerase chain reaction technique and were found to be significantly increased after treatment with the novel chalcone derivative 1m. Several microRNAs, including miR155, miR758, miR10b, miR145, miR33, and miR106b, which functionally inhibit ABCA1 expression were suppressed after treatment with 1m. Collectively, 1m increases ABCA1 expression in human THP-1 macrophages. The mechanisms involve the activation of the LXRα-ABCA1 pathway and suppression of certain microRNAs that regulate ABCA1 expression.

Palladium-Catalyzed 2,2,2-Trifluoroethoxylation of Aromatic and Heteroaromatic Chlorides Utilizing Borate Salt and the Synthesis of a Trifluoro Analogue of Sildenafil

A simple and convenient method was developed for the introduction of a 2,2,2-trifluoroethoxy group to various aromatic and heteroaromatic systems. The novel process utilizes aromatic chlorides as substrates, and tetrakis(2,2,2-trifluoroethoxy) borate salt as an inexpensive and readily available fluoroalkoxy source in a palladium-catalyzed cross-coupling reaction. The power of the developed methodology was demonstrated in the synthesis of a fluorous derivative of Sildenafil.

CARBONYL ERASTIN ANALOGS AND THEIR USE

The present invention provides, inter alia, compounds having the structure of formula (I): Compositions containing such compounds are also provided. Methods for using such compounds or compositions for treating or ameliorating the effects of a cancer havi

Phenanthrene Compound, Ramification Thereof And Drug Composition Containing Phenanthrene Compound Or Ramification And Used For Treating Tuberculosis

The present invention relates to a novel phenanthrene compound, a ramification thereof and a drug composition containing the phenanthrene compound or the ramification and used for preventing or treating tuberculosis. The above tuberculosis activity resistant compound has excellent activity for the drug-fast MDR-MTB, also has a characteristic of low cytotoxicity, and can be used as the drug composition used for preventing or treating tuberculosis.

Design, synthesis and pharmacology of 1,1-bistrifluoromethylcarbinol derivatives as liver X receptor β-selective agonists

A novel series of 1,3-bistrifluoromethylcarbinol derivatives that act as liver X receptor (LXR) β-selective agonists was discovered. Structure-activity relationship studies led to the identification of molecule 62, which was more effective (Emax) and selective toward LXRβ than T0901317 and GW3965. Furthermore, 62 decreased LDL-C without elevating the plasma TG level and significantly suppressed the lipid-accumulation area in the aortic arch in a Bio F1B hamster fed a diet high in fat and cholesterol. We demonstrated that our LXRβ agonist would be potentially useful as a hypolipidemic and anti-atherosclerotic agent. In this manuscript, we report the design, synthesis and pharmacology of 1,3-bistrifluoromethylcarbinol derivatives.

CARBONYL ERASTIN ANALOGS AND THEIR USE

The present invention provides, inter alia, compounds having the structure of formula (I): Compositions containing such compounds are also provided. Methods for using such compounds or compositions for treating or ameliorating the effects of a cancer havi